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Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we
present the largest sequencing study of osteosarcoma to date, comprising 112 childhood and
adult tumours encompassing all major histological subtypes. A key ﬁnding of our study is the
identiﬁcation of mutations in insulin-like growth factor (IGF) signalling genes in 8/112 (7%) of
cases. We validate this observation using ﬂuorescence in situ hybridization (FISH) in an
additional 87 osteosarcomas, with IGF1 receptor (IGF1R) ampliﬁcation observed in 14% of
tumours. These ﬁndings may inform patient selection in future trials of IGF1R inhibitors in
osteosarcoma. Analysing patterns of mutation, we identify distinct rearrangement proﬁles
including a process characterized by chromothripsis and ampliﬁcation. This process operates
recurrently at discrete genomic regions and generates driver mutations. It may represent
an age-independent mutational mechanism that contributes to the development of
osteosarcoma in children and adults alike.
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S
ince the introduction in the early 1980s of systemic
cytotoxic chemotherapy into treatment schedules, the
prognosis of osteosarcoma has essentially stalled, with
B40% of patients having incurable disease1. In an effort to
advance the understanding and treatment of osteosarcoma, the
genomic alterations that underpin this cancer require systematic
analysis. To date, the exomes or whole genomes of 110 cases
have been analysed, elucidating a number of features of the
osteosarcoma genome. Perry et al.2 found recurrent mutations in
the PI3K/mTOR (phosphatidylinositol-3-kinase/mammalian
target of rapamycin) pathway in a series of osteosarcomas
mainly studied by whole exome sequencing. In a whole genome
study of osteosarcoma, structural variants were identiﬁed as a
major source of driver mutation. Some of these variants occurred
in the context of chromothripsis, the shattering of chromosomes
resulting in copy number oscillations3. Using whole exome
sequencing combined with copy number arrays, Kovac et al.4
described genomic alterations in osteosarcoma indicative of
compromised homology-directed DNA repair.
Here, we report the somatic genetic changes of 112 childhood
and adult osteosarcomas. Our series encompasses treatment-
naive and pretreated osteosarcomas (Supplementary Data 1).
Tumours were chosen, based on availability of high-quality tissue,
to represent all major subtypes of osteosarcoma. Twelve tumours
arose in the context of a genetic predisposition to osteosarcoma
(Supplementary Data 1).
DNA from tumours and paired normal tissue was interrogated
by exome (n¼ 75) or whole genome sequencing (n¼ 37). For
every tumour copy number variants were derived, either from
SNP6 arrays (exome samples) or from whole genome sequencing
reads. In addition, where feasible, RNA sequencing was
performed (n¼ 7). Catalogues of somatic point mutations and
structural variants were compiled and analysed using the pipeline
of the Cancer Genome Project5. The previously established high
precision of our mutation calling pipeline was conﬁrmed through
resequencing 8% of coding indels and substitutions.
A key ﬁnding of our study was potentially actionable somatic
alterations in insulin-like growth factor (IGF) signalling genes
in a subset of cases. Furthermore, we describe a distinct pattern
of genomic rearrangement, chromothripsis ampliﬁcation, that
generates driver mutations across the osteosarcoma genome.
Results
Overview of somatic changes in 112 osteosarcomas. The burden
of coding indels and substitutions across the 112 tumours varied
from 3 to 316 mutations per tumour (median¼ 38; Suppleme-
ntary Data 1 and 2). The highest coding mutation burden was
observed in PD4901a, a tumour with microsatellite instability.
Analysis of 146,573 substitutions in the context of their
immediate 50 and 30 bases identiﬁed 9 mutational signatures
among 37 whole genomes (Supplementary Data 1 and 3). The
most prevalent signatures were 5 and 8 (ref. 6). Signature 5
represents an age-related mutational process. Signature 8 is of
unknown origin and has a striking preponderance in
osteosarcoma. Examination of the patterns of rearrangement
revealed three distinct cytogenetic conﬁgurations of the
osteosarcoma genome, discussed in more detail later.
A diverse range of cancer genes operates in osteosarcoma. We
deﬁned driver mutations in established cancer genes, considering
point mutations (substitutions and indels) and structural variants,
that is, ampliﬁcations, homozygous deletions and breakpoints
that disrupt genes or generate gene fusions. It should be noted
that rearrangements not associated with changes in copy number
or allelic balance can only be called in samples subjected to whole
genome sequencing. Furthermore, the high burden of structural
variation observed in osteosarcoma (Supplementary Fig. 1),
particularly ampliﬁcations, may risk overcalling putative driver
mutations. Consequently, we adopted a conservative strategy,
restricting our interest to high conﬁdence variants (see Methods).
Overall, we found a diverse landscape, comprising 67 different
cancer genes, with structural variants being the predominant
source of mutation (Fig. 1a; driver mutations of individual cases
are listed in Supplementary Data 1 and 4). These included
12 cancer genes not previously implicated in osteosarcoma
(Table 1). Statistical analyses for nonrandom enrichment in genes
and noncoding regulatory sites did not identify novel candidate
cancer genes. A number of novel gene fusions were discovered
that are predicted to be in-frame, although none was recurrent
(Supplementary Data 5). Similarly, no recurrent gene fusions
were found in transcriptomic reads.
Recurrent mutations of IGF signalling genes. We observed
recurrent mutations in genes mediating signalling via the IGF
receptor (Fig. 1). Mutations in signalling cascades downstream
of IGF1 receptor (IGF1R) have previously been found in
osteosarcoma2. Here, we found mutated genes at the level of the
receptor itself in 7% of cases: focal ampliﬁcation of IGF1R (n¼ 3)
and of IGF1 (n¼ 2); frameshift indels in the recessive cancer
genes, IGF2R (n¼ 2) and IGFBP5 (n¼ 1). These alterations,
which were mutually exclusive, would be predicted to result
in activation of IGF1R signalling (Fig. 1d)7–9. If we include
driver mutations downstream of IGF1R affecting the PI3K or
Ras/Raf/mitogen-activated protein kinase signalling pathway,
perturbed IGF1R signalling may be a driving force in up to
27% of tumours in our series.
Owing to its fundamental role in mediating cellular growth,
IGF signalling has long been implicated in the pathogenesis of
osteosarcoma1,10–15. A particular focus of research has been
IGF1R that has been targeted in phase I/II clinical trials of IGF1R
inhibitors in osteosarcoma16–18. Given this prior interest, we
assessed IGF1R copy number in an extension cohort of 87 cases of
childhood and adult osteosarcoma. Using ﬂuorescence in situ
hybridization (FISH), which allows sensitive and speciﬁc
examination of individual tumour cells, we found high-level
ampliﬁcation of IGF1R, deﬁned as 15 copies or more, in 12/87
(14%) cases (Supplementary Data 6 and Supplementary Fig. 2).
These ﬁndings justify the reinvigoration of efforts to target IGF1R
therapeutically in patients, preselected based on tumour
genotype. Given the presence of driver mutations in signalling
genes downstream of IGF1R in some cases, IGF1R signalling may
require targeting at different levels simultaneously to overcome
possible intrinsic resistance to IGF1R inhibition alone.
Patterns of rearrangement deﬁne distinct tumour groups.
Analysis of patterns of rearrangements in 37 tumours revealed
three cytogenetic conﬁgurations of the osteosarcoma genome.
A minority of tumour genomes (4/37) exhibited few or no
rearrangements. Given a tumour content of 38% or more in these
four osteosarcomas, lack of tumour cells was unlikely to account
for the quiet rearrangement proﬁles. A second proﬁle comprised
11/37 genomes that harboured chromothripsis on one or more
chromosomes. A striking and rare example is PD13494a in which
chromosome 17 was singularly mutated by chromothripsis
with the remaining genome devoid of rearrangements (Fig. 2a).
All discernible driver events of this tumour were caused by the
disruption on chromosome 17, raising the possibility that
PD13494a arose from a single event of chromothripsis. The third
proﬁle, seen in 22/37 genomes, was characterized by a distinct
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copy number pattern of combined chromothripsis and ampliﬁ-
cation (Fig. 2b–d).
Chromothripsis ampliﬁcation generates driver mutations.
Chromothripsis ampliﬁcation affected discrete genomic regions
recurrently, including chromosomes 5, 12 and 17 (Fig. 3a–c).
Such recurrence may represent chromosomal fragility or be the
result of selection for driver events. Detailed annotation of
the consequences of rearrangements in these regions across the
37 genomes supports the latter view (Table 2 and Fig. 3). It
showed that chromothripsis ampliﬁcation generated multiple
driver events. On chromosome 12, chromothripsis ampliﬁcation
was seen in 6/37 cases, resulting in the co-ampliﬁcation of
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Figure 1 | The cancer gene landscape of osteosarcoma. The driver mutations of 112 osteosarcomas are shown in a. For each mutated cancer gene the
percentage of 112 tumours with at least one driver mutation is shown, subdivided by mutation type. Blue: point mutation (substitutions; indels). Green:
structural variant (ampliﬁcation; homozygous deletion; disruptive breakpoint). (b) Driver events that were found in IGF1R signalling genes operative at the level
of IGF1R. Blue square: ampliﬁcation. Red circle: truncating mutation. An example of an amplicon is shown in c, found in case PD7193a. The x axis shows
genomic position in mega bases and the y axis shows absolute copy number. Each dot in the plot represents the copy number of a particular genomic position.
Lines and arcs: breakpoint with rearrangements coded by colour. Brown: tandem duplication; blue: deletion; green and turquoise: inversion; grey with
arrowheads: interchromosomal rearrangement. (d) The key components of IGF signalling7–9. At the level of the cell membrane, IGF signalling is mediated by
IGF1R. IGF2R is a nonsignalling receptor that acts as a negative regulator of IGF1R. A number of circulating binding proteins modulate the function of IGF1R
signalling, including IGFBP5 that is thought to inhibit IGF1R. Note that both IGF1 and IGF2 have autocrine, paracrine as well as endocrine sources7–9.
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CDK4/MDM2 (Figs 2b and 3a and Table 2). This co-amplicon is
well established as a driver event in different types of human
cancer including in osteosarcoma. CDK4/MDM2 co-ampliﬁcation
was predominant in parosteal osteosarcoma, and was also
present in other subtypes consistent with previous reports
(Supplementary Data 1). Of note, in 2/37 genomes, additional
copies of the CCND2 oncogene were gained in the context
of CDK4/MDM2 ampliﬁcation on chromosome 12. On
chromosome 5, in four cases chromothripsis ampliﬁcation
resulted in gains of the RICTOR oncogene combined with copy
number gains of TERT in 2/37 cases (Figs 2c and 3b, Table 2
and Supplementary Data 7). In ﬁve tumours, chromothripsis
ampliﬁcation was present on the short arm of chromosome 17
and the immediate peri-centromeric region (Figs 2d and 3c).
Three driver events were generated there: ampliﬁcation of the
COPS3 oncogene19 and disruption of TP53 and NF1 by copy
number loss or by insertion of disrupting breakpoints into the
gene footprint (Fig. 3c and Table 2). Taken together, these
ﬁndings identify chromothripsis ampliﬁcation as a mechanism
responsible for multiple driver events. Of note, in two tumours
chromothripsis ampliﬁcation co-generated drivers on different
chromosomes (Table 2).
Gene expression in areas of chromothripsis ampliﬁcation. To
further examine the consequences of chromothripsis ampliﬁca-
tion, we analysed gene expression patterns in regions of
recurrent chromothripsis ampliﬁcation. We found signiﬁcantly
increased variance of gene expression levels in the presence of
chromothripsis ampliﬁcation (P¼ 2 10 5, binomial test;
Supplementary Fig. 3). It is therefore conceivable that regions of
chromothripsis ampliﬁcation contain general gene dysregulation
in addition to speciﬁc driver events.
A pan-cancer search for chromothripsis ampliﬁcation. As the
chromosome 12 CDK4/MDM2 co-amplicon is present in many
different tumour types, it is conceivable that co-generation of
drivers on chromosomes 5 and 17 can also be found in tumours
other than osteosarcoma. We therefore analysed the copy number
proﬁles ofB13,000 tumours. Our ﬁnding that the CDK4/MDM2
co-amplicon was associated with CCND2 gain was also seen in
glioblastoma multiforme (Fig. 3d). The pattern of 17p loss in
conjunction with COPS3 ampliﬁcation was present in a group of
267 soft tissue sarcomas, particularly in leiomyosarcoma (Fig. 3e).
The co-ampliﬁcation of TERT and RICTOR was only seen in
osteosarcoma.
Childhood versus adult osteosarcoma. Osteosarcoma is one
of few solid cancers with a bimodal age distribution, with the
incidence peaking during adolescence and in old age. Our study
has not revealed any genomic differences between tumours of
different age groups (Supplementary Data 8). The only exception
was the burden of substitutions attributable to clockwise
mutational processes 1 and 5 that correlates with age (P¼ 0.005,
Pearson’s product-moment correlation). Chromothripsis ampli-
ﬁcation was present in patients of all ages, indicating that it is an
age-independent rearrangement process.
Discussion
Sequencing efforts of recent years have repeatedly shown that
rare tumours tend to lack genetic diversity and are often driven by
highly recurrent, in some cases pathognomonic driver mutations20.
Osteosarcoma is an exception. Our ﬁndings along with previous
studies have demonstrated that osteosarcoma exhibits a degree of
mutational diversity akin to the most common types of human
cancer. The diversity is mainly driven by complex rearrangement
processes, chromothripsis and chromothripsis ampliﬁcation that
for unknown reasons predominate in osteosarcoma. This is
reﬂected in the burden of focal ampliﬁcations in osteosarcoma
that is higher than in any other human cancer studied to date
(Supplementary Fig. 1). It is conceivable that rearrangement
processes are particularly active in cells of the osteosarcoma lineage,
driven intrinsically or by unknown mutagens, thus leading to the
apparent enrichment of complex structural variation.
We identiﬁed chromothripsis ampliﬁcation as a distinct
pattern of rearrangement that is present in childhood and adult
osteosarcoma. If it originated in chromothripsis, it would raise
the possibility that formation of multiple drivers might have been
seeded in single cellular catastrophes. Consistent with this
concept the MDM2/CDK4 co-amplicon has been studied in
detail in liposarcoma and was shown to result from initial
chromothripsis, followed by ampliﬁcation and breakage–fusion–
bridge cycles21. The same process is likely to operate across the
osteosarcoma genome, given the strikingly similar patterns of
rearrangement that we observed in regions of chromothripsis-
ampliﬁcation.
We have been able to dissect some of the diversity of
osteosarcoma by identifying a subgroup of tumours driven by
potentially actionable alterations in IGF1R signalling and by
deﬁning distinct patterns of rearrangement. However, the
genomes of substantially larger series of tumours, ideally
embedded in prospective observational trials, will be required to
develop a complete picture of the osteosarcoma genome.
Table 1 | Cancer genes not previously implicated in osteosarcoma.
Gene Number of mutated samples (n¼ 112) Truncating point mutation Disruptive break point Homozygous deletion Amplicon
DNM2 4 0 4 0 0
ERBB4 4 1 0 3 0
TERT 4 0 0 0 4
ARID1B 3 0 3 0 0
CCND2 3 0 0 0 3
IGF1R 3 0 0 0 3
RBL2 3 2 1 0 0
SUFU 3 1 2 0 0
FAS 2 1 0 1 0
IGF2R 2 2 0 0 0
MLL3 2 0 2 0 0
SETD2 2 1 1 0 0
Listed are mutated cancer genes in our series of 112 osteosarcoma. The number of mutated samples and mutation class for each gene are listed.
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Methods
Patient samples. Informed consent was obtained from all subjects and
ethical approval obtained from Cambridgeshire 2 Research Ethics Service
(reference 09/H0308/165). Norwegian samples were collected by approval from the
ethics committee of Southeast Norway (reference S-06133). Collection and use of
patient samples were approved by the appropriate institutional review board of
each institution.
Sequencing. Tumour DNA was derived from fresh frozen tissue reviewed by a bone
pathologist (A.M.F.). Normal tissue DNA was derived from adjacent normal tissue or
blood samples. Whole genome and exome sequencing was performed using the
Illumina HiSeq 2000 or 2500 platform5, using 100 base paired-end sequencing.
For whole genome sequencing we followed the Illumina no-PCR library protocol to
construct short insert 500 bp libraries, prepare ﬂowcells and generate clusters.
The average coverage of tumours was at least 40 and of normal DNA at least 30 .
For exome sequencing coding DNA was enriched for using target enrichment by bait
capture (Agilent). We aimed to cover 70% of coding regions with at least 30 reads.
Copy number calling. Copy number calls were derived from SNP6 arrays
(exome sample) or whole genome sequences (9 cases) using the ASCAT22 or
ascatNgs algorithm23, respectively. The algorithms were also used to determine
tumour content of tumour samples.
Variant detection. The variant calling pipeline of the Cancer Genome Project,
Wellcome Trust Sanger Institute, was used to call somatic mutations5. We used the
following algorithms with standard settings and no additional prost-processing:
CaVEMan for substitutions; the Pindel algorithm for indels; and the BRASS
algorithm for rearrangements.
Variant validation. The high precision of the variant calling pipeline of the
Cancer Genome Project, Wellcome Trust Sanger Institute, has been consistently
demonstrated in previous experiments5,24–29. Here, we conﬁrmed this through a
dedicated validation experiment. We obtained informative validation reads for 8%
of coding mutations, 161 indels and 209 substitutions, from 43 tumours. Of these,
B90% of substitutions andB80% of indels were shown to be true, in keeping with
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Figure 2 | Patterns of rearrangement in osteosarcoma. In a the rare case of a tumour is shown in which rearrangements are conﬁned to a single
chromosome as a consequence of chromothripsis. This causes multiple driver events in this tumour, that is, loss of heterozygosity (LOH) of TP53 and
MAP2K4 and disruption of NF1 by insertion of breakpoints into the gene footprint. (b–d) Examples of chromothripsis-ampliﬁcation. The x axis shows
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position. Lines and arcs: breakpoint with rearrangements coded by colour. Brown: tandem duplication; blue: deletion; green and turquoise: inversion;
grey with arrowheads: interchromosomal rearrangement.
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previously published performances of our pipeline. All driver events were further
scrutinized and only included in the driver table if they passed manual inspection.
As for rearrangements, we only included breakpoints in this data set that had been
validated by reconstruction at a base pair resolution.
Driver analysis of mutations in cancer genes and search for novel drivers. We
employed a deﬁned strategy to manually curate driver events from the identiﬁed
somatic mutations, as previously reported5. We only considered variants as
potential drivers if they presented in established cancer genes. Mutations in
recessive cancer genes were considered if they truncated the gene footprint, that is,
truncating substitutions, out-of-frame indels, disruptive rearrangement breakpoints
and homozygous deletions. An additional requirement for homozygous deletions
was that the deleted segment had to be focal (that is,o1Mb in size). Mutations in
oncogenes were considered driver events if they resided at previously reported
canonical hot spots (point mutations) or ampliﬁed the intact gene. Ampliﬁcations
additionally had to be focal (o1Mb in size) and increase the copy number of
oncogenes to a minimum of 5 or 9 copies in diploid and tetraploid samples,
respectively. To search for driver variants in novel cancer genes or in noncoding
regions, we employed previously developed statistical methods that identify
signiﬁcant enrichment of mutations, taking into account various confounders such
as overall mutation burden and local variation in the mutability of the genomic
region5.
Extension FISH study. A cohort of 87 further cases of childhood and adult
osteosarcoma were examined by FISH for copy number of IGF1R, using previously
described methods30. In brief, deparafﬁnized sections were pretreated by a pressure
cooking for 5min and subsequently incubated in pepsin solution at 37 C for
50min. Probes were applied to tissue sections and denatured at 72 C, and followed
by hybridization overnight at 37 C. After hybridization, the sections were washed
and mounted by 40,6-diamidino-2-phenylindole with coverslips.
Meta-analysis of copy number changes in human cancer. Copy number
changes across 13,241 tumours were called. CEL ﬁles derived from Affymetrix
SNP6 arrays were processed using the PennCNV libraries31 to obtain logR and
BAF data. The logR was subsequently corrected for GC content to decrease wave
artefacts. Copy number proﬁles for all tumour samples were inferred from the
corrected data using the ASCAT computational framework version 2.4.2 (ref. 22).
Using bespoke R code, aggregate genome wide copy number proﬁles for each
tumour type were generated, visualizing the ﬁrst and third quantiles as well as the
TP53
NF1
0 50
2
0
–1
2
0
CCND2
MDM2
CDK4
COPS3
2
0
CCND2
MDM2CDK4
Co
py
 n
um
be
r c
ha
ng
e 
(lo
g2
)
0 50 100
Chromosome 12 position (Mb)
a
2
0
–1
50
Chromosome 5 position (Mb)
TERT RICTOR
Co
py
 n
um
be
r c
ha
ng
e 
(lo
g2
)
0
b
Co
py
 n
um
be
r c
ha
ng
e 
(lo
g2
)
Chromosome 17 position (Mb)
0 50
TP53
NF1
COPS3
2
0
–1
c
d
Co
py
 
n
u
m
be
r c
ha
ng
e
 (lo
g2
)
Co
py
 n
um
be
r c
ha
ng
e 
(lo
g2
)
e
Chromosome 17 position (Mb)
Chromosome 12 position (Mb)
0 50 100
Osteosarcoma
Osteosarcoma
Osteosarcoma
Glioblastoma multiforme
Soft tissue sarcoma
Figure 3 | Aggregate copy number proﬁles. Aggregate copy number proﬁles of chromosomes 12 (a), 5 (b) and 17 (c) in 112 osteosarcomas are shown in
comparison with chromosome 12 of 643 cases of glioblastoma multiforme (d) and to chromosome 17 of 267 soft tissue sarcomas (e). Using copy number
calls from this and other studies, aggregate copy number proﬁles for each chromosome and tumour type were generated. Blue shaded area highlights the
ﬁrst and third quartiles of copy numbers in each genomic position. Black represents the mean copy number in each genomic position. The x axis shows
genomic position and the y axis shows copy number change (log2). Putative target genes are indicated with arrows.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15936
6 NATURE COMMUNICATIONS | 8:15936 | DOI: 10.1038/ncomms15936 | www.nature.com/naturecommunications
mean. The tumours included in this analysis were: osteosarcoma (n¼ 112; this
series); chondrosarcoma (n¼ 38 (ref. 32)); chordoma (n¼ 38; unpublished data);
breast cancers (n¼ 1,449; sourced from The Cancer Genome Atlas (TCGA) and
International Cancer Genome Consortium (ICGC)5); acute myeloid leukaemia
(n¼ 200; TCGA); adrenocortical carcinoma (n¼ 90; TCGA); bladder urothelial
carcinoma (n¼ 439; TCGA); brain lower grade glioma (n¼ 531; TCGA); breast
invasive carcinoma (n¼ 1,175; TCGA); cervical squamous cell carcinoma and
endocervical adenocarcinoma (n¼ 307; TCGA); cholangiocarcinoma (n¼ 49;
TCGA); colon adenocarcinoma (n¼ 643; TCGA); oesophageal carcinoma
(n¼ 192; TCGA); glioblastoma multiforme (n¼ 589; TCGA); head and neck
squamous cell carcinoma (n¼ 590; TCGA); kidney chromophobe cancer (n¼ 66;
TCGA); renal clear cell carcinoma (n¼ 631; TCGA); renal papillary cell carcinoma
(n¼ 335; TCGA); hepatocellular carcinoma (n¼ 415; TCGA); lung
adenocarcinoma (n¼ 715; TCGA); lung squamous cell carcinoma (n¼ 588;
TCGA); lymphoid neoplasm diffuse large B-cell lymphoma (n¼ 48; TCGA);
mesothelioma (n¼ 87; TCGA); ovarian serous cystadenocarcinoma (n¼ 611;
TCGA); pancreatic adenocarcinoma (n¼ 191; TCGA); pheochromocytoma and
paraganglioma (n¼ 186; TCGA); prostate adenocarcinoma (n¼ 562; TCGA);
rectum adenocarcinoma (n¼ 183; TCGA); soft tissue sarcoma (n¼ 268; TCGA);
cutaneous melanoma (n¼ 475; TCGA); stomach adenocarcinoma (n¼ 529;
TCGA); testicular germ cell tumours (n¼ 156; TCGA); thymoma (n¼ 126;
TCGA); thyroid carcinoma (n¼ 543; TCGA); uterine carcinosarcoma (n¼ 57;
TCGA); uterine corpus endometrial carcinoma (n¼ 583; TCGA); and uveal
melanoma (n¼ 80; TCGA).
Extraction of substitution signatures. Substitution signatures were extracted
using the nonnegative matrix factorization algorithm6.
Analysis of gene expression variance. To assess variance of gene expression
levels in areas of chromothripsis ampliﬁcation, we identiﬁed genomic regions of
chromothripsis ampliﬁcation in tumours for which we had RNA sequencing
data. For all genes in these regions we measured the variability of expression by
calculating the variance of the TPM quartiles. To assess whether gene expression
was more variable in samples and regions containing chromothripsis ampliﬁcation,
we compared the variance in TPM quantiles for each region between samples with
chromothripsis ampliﬁcation with those that are copy number neutral. If the
variability of gene expression were uncorrelated with the copy number state of the
region, we would expect that the median variance for the control samples to be
higher than the chromothripsis-ampliﬁed samples 50% of the time. We tested this
null hypothesis against the alternative hypothesis that the variance is higher in
regions of chromothripsis ampliﬁcation using a binomial test.
Statistical analyses. Other statistical tests employed are detailed elsewhere in this
Methods section or in Figure legends.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files or
from the corresponding author on reasonable request. Sequencing data have been
deposited at the European Genome-Phenome Archive (http://www.ebi.ac.uk/ega/)
that is hosted by the European Bioinformatics Institute (accession numbers
EGAD00001000107, EGAS00001000196 and EGAD00001000147).
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